Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775377 | 0.85 | PNMT (0.30) | PNMT | |
| SCHEMBL15857507 | 0.81 | MAOB (0.42) | PNMTMAOAMAOBTAAR1DPP4 | |
| SCHEMBL4388225 | 0.77 | ALOX5 (0.41) | PNMTALOX5MAOAMAOBCFTR | |
| SCHEMBL1461770 | 0.77 | ALOX5 (0.44) | ALOX5MAOAMAOBAHRCHRM3 | |
| SCHEMBL23028838 | 0.76 | LMNA (0.39) | PNMTALOX5MAOAMAOBCFTR | |
| SCHEMBL5198267 | 0.75 | KDM4E (0.45) | PNMTMAOAMAOBTAAR1CFTR | |
| SCHEMBL7031351 | 0.74 | ALOX5 (0.38) | PNMTALOX5MAOAMAOBCFTR | |
| SCHEMBL11855407 | 0.74 | ALOX5 (0.38) | PNMTALOX5MAOAMAOBCFTR | |
| SCHEMBL3729918 | 0.74 | ALOX5 (0.38) | PNMTALOX5MAOAMAOBCFTR | |
| SCHEMBL29722 | 0.74 | CHRM3 (0.46) | ALOX5MAOAMAOBCFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20210071181-A1 | PHARMACEUTICAL COMPOSITION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2021-03-11 | — | — | US | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| EP-3502255-A1 | PHARMACEUTICAL COMPOSITION | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-26 | — | — | EP | disclosed |
| US-20190071672-A1 | Pharmaceutical Composition | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-03-07 | — | — | US | disclosed |
| EP-3431602-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-01-23 | — | — | EP | disclosed |
| EP-2666859-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-01-02 | — | — | EP | disclosed |
| US-20180195062-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| EP-2264172-B1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA EXPRESSION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2017-09-27 | — | — | EP | disclosed |
| US-9738894-B2 | Short interfering RNA (siRNA) analogues | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-08-22 | — | — | US | disclosed |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | ENZON PHARMACEUTICALS, INC | 2005-01-20 | — | — | US | disclosed |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | SANTARIS PHARMA A/S | 2004-12-09 | — | — | US | disclosed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | disclosed |
| WO-2004083430-A2 | SHORT INTERFERING RNA (siRNA) ANALOGUES | SANTARIS PHARMA A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2003085110-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | SANTARIS PHARMA A/S (DK) | 2003-10-16 | — | — | WO | disclosed |
| US-3971658-A | Imaging process employing friction charging in the presence of an electrically insulating liquid | XEROX CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | HRAS, KRAS, NRAS | PNMT 4731/4885ALOX5 3973/4885MAOA 2906/4885 |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | TXN, TXN2, TXNRD3 | PNMT 2958/4885ALOX5 1830/4885MAOA 1083/4885 |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | HIF1AN, HIF1A, HYOU1 | PNMT 2379/4885ALOX5 2181/4885MAOA 4525/4885 |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | BIRC5, XIAP, BIRC3 | PNMT 3791/4885ALOX5 3254/4885MAOA 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.